Skip to main content
Top
Published in: Journal of Translational Medicine 1/2010

Open Access 01-11-2010 | Oral presentation

Sustained T cell Rap1 activation protects against Experimental Autoimmune Encephalomyelitis (EAE) via modulation of T cell responses

Authors: G Franco Salinas, S Krausz, W Dontje, P P Tak, D Baeten, K Reedquist

Published in: Journal of Translational Medicine | Special Issue 1/2010

Login to get access

Excerpt

Rap1 is signalling molecule that modulates T lymphocyte trafficking and activation upon antigen stimulation. We demonstrated that transgenic mice with T cells expressing constitutively active Rap1 (RapV12) are protected from experimental arthritis. Here, we aimed to identify the mechanisms of protection by using a TCR transgenic model of MOG-induced EAE (2D2 mice). …
Metadata
Title
Sustained T cell Rap1 activation protects against Experimental Autoimmune Encephalomyelitis (EAE) via modulation of T cell responses
Authors
G Franco Salinas
S Krausz
W Dontje
P P Tak
D Baeten
K Reedquist
Publication date
01-11-2010
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue Special Issue 1/2010
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-S1-O6

Other articles of this Special Issue 1/2010

Journal of Translational Medicine 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine